Johnson & Johnson Buys Egea Biosciences
From Bloomberg News
Johnson & Johnson, one of the world’s largest healthcare product makers, bought closely held Egea Biosciences Inc. Terms weren’t disclosed.
San Diego-based Egea, which has about 39 employees, will join Johnson & Johnson’s Centocor unit.
Egea’s technologies will help Centocor -- which introduced one of the earliest antibody medicines, ReoPro -- develop other protein-based biotechnology medicines.
Shares of New Brunswick, N.J.-based Johnson & Johnson fell 7 cents to $54.63 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
